Daily oral GLP-1 medication linked to similar weight loss across three menopausal stages

New analyses to be presented at the annual meeting of the European Association for the Study of Diabetes (EASD) in Milan, Italy, Sept. 28–Oct. 2, show that orforglipron, a daily oral medication for weight loss and type 2 diabetes, was associated with similar weight loss among women of different ages and at different life stages: before, during and after menopause.

≈